We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.51 | 3.02 | 4.00 | 202,000 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 7.80 | 10.36M |
TIDMPRM
RNS Number : 7216K
Proteome Sciences PLC
11 July 2017
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Notice of Results
Proteome Sciences will announce its interim results for the six months ended 30 June 2017 on 25 July 2017.
For further information: Proteome Sciences plc Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043 2116 Dr Ian Pike, Chief Scientific Officer Geoff Ellis, Finance Director finnCap Limited (Nominated Adviser/Broker) Tel: +44 (0)20 7220 Geoff Nash/James Thompson 0500 Tony Quirke (broking) IFC Advisory (Financial PR and IR) Tim Metcalfe/Graham Tel: +44 (0)20 3053 Herring/Miles Nolan 8671
Notes for editors:
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) ) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFSIDVILLID
(END) Dow Jones Newswires
July 11, 2017 07:00 ET (11:00 GMT)
1 Year Proteome Sciences Chart |
1 Month Proteome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions